Halozyme Therapeutics (HALO) Return on Capital Employed Growth (1y) (2012 - 2026)
Halozyme Therapeutics (HALO) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 2,400.00 |
| 10 | Halozyme Therapeutics | 9.67 Bn | 9.35 Bn | 297.47 Mn | -728.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -728.00 |
| Dec 31, 2025 | -690.00 |
| Sep 30, 2025 | 3,206.00 |
| Jun 30, 2025 | 1,160.00 |
| Mar 31, 2025 | 727.00 |
| Dec 31, 2024 | 841.00 |
| Sep 30, 2024 | 674.00 |
| Jun 30, 2024 | 401.00 |
| Mar 31, 2024 | 827.00 |
| Dec 31, 2023 | 432.00 |
| Sep 30, 2023 | 335.00 |
| Jun 30, 2023 | -33.00 |
| Mar 31, 2023 | -1,481.00 |
| Dec 31, 2022 | -1,131.00 |
| Sep 30, 2022 | -1,536.00 |
| Jun 30, 2022 | -1,066.00 |
| Mar 31, 2022 | -32.00 |
| Dec 31, 2021 | -8,362.00 |
| Sep 30, 2021 | 2,299.00 |
| Jun 30, 2021 | 3,593.00 |